Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 13C-Pyruvate MRI in TBI and SAH
NCT06103201Phase 1Recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Oct 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hyperpolarized 13C-pyruvate in traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) (3 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Apparent conversion rate constant pyruvate to lactate, Lactate-to-pyruvate ratio and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
hyperpolarized 13C-pyruvate
03
Conditions
traumatic brain injury (TBI)subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT06103201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103201.